{"id":"NCT04143061","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","officialTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-30","primaryCompletion":"2023-01-28","completion":"2023-01-28","firstPosted":"2019-10-29","resultsPosted":"2025-02-03","lastUpdate":"2025-02-03"},"enrollment":1328,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Immunization","Healthy Volunteers"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine","otherNames":["MenACYW conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine","otherNames":["Menactra®"]},{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine","otherNames":["Quadri Meningo™"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"ACTIVE_COMPARATOR"},{"label":"Group 5","type":"EXPERIMENTAL"},{"label":"Group 6","type":"ACTIVE_COMPARATOR"},{"label":"Group 7","type":"EXPERIMENTAL"},{"label":"Group 8","type":"ACTIVE_COMPARATOR"}],"summary":"This will be a Phase III, modified double-blind (open-label for toddlers in India), randomized, parallel-group, active-controlled, step-wise, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adults, adolescents, children, and toddlers in India and a modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adolescents and children in RSA.","primaryOutcome":{"measure":"Group 5 + 7 and Group 6 + 8: Percentage of Participants Who Achieved Antibody Titers ≥1:8 Against Meningococcal Serogroups A, C, Y, and W","timeFrame":"Day 30 (30 days post-vaccination on Day 0)","effectByArm":[{"arm":"Group 5 + Group 7: MenACYW Conjugate Vaccine","deltaMin":89.6,"sd":null},{"arm":"Group 6 + Group 8: Menactra®","deltaMin":83.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":20},"locations":{"siteCount":17,"countries":["India","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":98},"commonTop":["Injection Site Pain","Headache","Myalgia","Malaise","Pyrexia"]}}